Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort
Our findings support that pharmacogene variants influence transplant outcomes. Notable associations include survival related to ABCB1 and ABCC2 variants, tumor occurrence linked to CYP2B6 rs3745274, and renal function affected by multiple pharmacogenes. Variants in CYP2C19 and SLCO1B1 significantly impacted tacrolimus pharmacokinetics and nephrotoxicity risk. These results underline the importance of pharmacogenetic testing for personalized management in kidney transplantation, although further validation in larger cohorts is necessary.
Authors
- Gladys G. Olivera (ORCID: https://orcid.org/0000-0002-7698-2122)
- María José Herrero (ORCID: https://orcid.org/0000-0002-6042-4185)
- Salvador F. Aliño (ORCID: https://orcid.org/0000-0002-7830-8713)
- María Isabel Beneyto
- Julio Hernández Jaras (ORCID: https://orcid.org/0000-0003-1250-1550)
- Fabiana Dalla Vecchia Genvigir (ORCID: https://orcid.org/0000-0002-7112-2879)
- Luis Sendra (ORCID: https://orcid.org/0000-0003-3176-9763)
- Enrique G. Zucchet
Institutions
- Universitat de València (ES)
- Universidade de São Paulo (BR)
- Hospital Universitari i Politècnic La Fe (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
Publication Details
- Journal
- Current Research in Pharmacology and Drug Discovery
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.crphar.2025.100230
- Citations
- 1
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.99
Funders
- Instituto de Salud Carlos III